Aspire Biopharma Holdings (ASBP) Other Accumulated Expenses (2022 - 2026)

Aspire Biopharma Holdings (ASBP) has 5 years of Other Accumulated Expenses data on file, last reported at $353679.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses changed 0.0% year-over-year to $353679.0 in Q1 2026; TTM through Mar 2026 was $353679.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $353679.0, up 218.56% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $353679.0, roughly flat from $353679.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for ASBP reached as high as $353679.0 in Q1 2025 and fell as low as $111026.0 in Q4 2024.
• Historically, Other Accumulated Expenses has averaged $266962.8 across 5 years, with a median of $283939.0 in 2024.
• Across the five-year window, Other Accumulated Expenses sank 53.53% in 2024 and jumped 218.56% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $122689.0 in 2022, then soared by 94.75% to $238939.0 in 2023, then sank by 53.53% to $111026.0 in 2024, then soared by 218.56% to $353679.0 in 2025, then changed by 0.0% to $353679.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $353679.0 in Q1 2026, $353679.0 in Q4 2025, and $353679.0 in Q3 2025.